Quinazoline derivatives represent a cornerstone in the development of targeted cancer therapies, particularly tyrosine kinase inhibitors. These complex organic compounds, characterized by their fused bicyclic structure containing two nitrogen atoms, are pivotal in the synthesis of many life-saving medications. For pharmaceutical researchers and product formulators, understanding the utility and sourcing of these intermediates is critical.

One such crucial compound is N4-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazoline-4,6-diamine (CAS 267243-68-5). This specific quinazoline derivative serves as a key intermediate in the synthesis of Canertinib, an irreversible pan-HER inhibitor that has shown promise in treating various forms of cancer, including non-small cell lung cancer and breast cancer. The precise structure and high purity of this intermediate are essential to ensure the efficacy and safety of the final active pharmaceutical ingredient (API).

Researchers often seek reliable manufacturers and suppliers for such specialized intermediates. When looking to buy this quinazoline derivative, it's important to partner with companies that can guarantee high purity (≥98.0%), consistent quality, and secure supply chains. The availability of this compound, often supplied in a light yellow to yellow powder or crystal form, facilitates its integration into complex synthesis processes. Many pharmaceutical companies and contract research organizations (CROs) rely on established suppliers in regions like China for cost-effective and high-quality sourcing.

The ongoing research into quinazoline-based compounds continues to uncover new therapeutic applications. Their ability to inhibit various kinases and signaling pathways makes them valuable targets for drug discovery. For scientists and chemists working in this field, securing a dependable source for intermediates like N4-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazoline-4,6-diamine is fundamental to accelerating their research and bringing new treatments to patients faster. Engaging with a reputable chemical supplier ensures access to the quality materials needed to drive innovation in cancer therapy.